Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies

Figure 4

(a) Alternate Baseline Platelet Count Cohorts—Proportion of patients not requiring a platelet transfusion or rescue procedure for bleeding—Pooled data from ADAPT-1 and ADAPT-2 (Full analysis set). ^aResponders were defined as patients not requiring a platelet transfusion or any rescue procedure for bleeding after randomization and up to 7 days following a scheduled procedure. ^bAlternate Low Baseline Platelet Count Cohort included patients with a platelet count of <35 × 10⁹/L. ^cAlternate High Baseline Platelet Count Cohort included patients with a platelet count of 35 to ≤50 × 10⁹/L. ^dCombined Baseline Platelet Count Cohort included patients with a platelet count of <50 × 10⁹/L. ∆ value represents the difference of proportion versus placebo = proportion of Responders for avatrombopag minus the proportion of Responders for placebo. -value is based on Cochran–Mantel–Haenszel Test stratified by the risk of bleeding associated with the scheduled procedure. CI = confidence interval. (b) Alternate secondary efficacy endpoint analysis—Summary of proportion of patients that achieved platelet count ≥50 × 10⁹/L and an increase of ≥20 × 10⁹/L on Procedure Day—Pooled data from ADAPT-1 and ADAPT-2 (Full Analysis Set). ^aLow Baseline Platelet Count Cohort included patients with a platelet count of <40 × 10⁹/L. ^bHigh Baseline Platelet Count Cohort included patients with a platelet count of ≥40 to <50 × 10⁹/L. ^cCombined Baseline Platelet Count Cohort included patients with a platelet count of <50 × 10⁹/L. ∆ value represents the difference of proportion versus placebo = proportion for avatrombopag minus the proportion for placebo. 95% CI is calculated based on normal approximation. -value is based on Cochran–Mantel–Haenszel test stratified by the risk of bleeding associated with the scheduled procedure. CI = confidence interval.

(a)

(b)